Isomorphic Labs

Isomorphic Labs Limited[1] is a London-based drug discovery company, which uses artificial intelligence for drug discovery.[2][3][4] Isomorphic Labs was incorporated on February 4, 2021 and announced on November 5, 2021.[2][5] It was established under Alphabet Inc. as a spin-off from its AI research lab Deepmind.[2][3][5] It is led by Demis Hassabis.[3]

The company draws upon Deepmind's AlphaFold 2 technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery.[5][6]

In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland.[5][7]

References
  1. "ISOMORPHIC LABS LIMITED overview - Find and update company information - GOV.UK". Companies House. February 24, 2021. Retrieved August 20, 2023.
  2. Shead, Sam (November 5, 2021). "Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs". CNBC. Archived from the original on November 5, 2021. Retrieved November 9, 2021.
  3. Coldewey, Devin (November 4, 2021). "Isomorphic Labs is Alphabet's play in AI drug discovery". TechCrunch. Retrieved August 23, 2022.
  4. Crist, Ry (November 4, 2021). "Alphabet launches Isomorphic Labs, an AI-driven drug discovery startup". CNET.
  5. Criddle, Cristina; Johnston, Ian (December 3, 2022). "DeepMind spin-off steps up effort to use AI to create new drugs". Financial Times. Archived from the original on December 5, 2022. Retrieved April 28, 2023.
  6. Quach, Katyanna (November 8, 2021). "Alphabet launches new AI drug discovery startup, Isomorphic Labs, led by DeepMind CEO". The Register. Archived from the original on November 27, 2022. Retrieved April 28, 2023.
  7. Aaron Hurst (December 5, 2022). "DeepMind spin-off Isomorphic Labs announces drug discovery scale plans". Information Age.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.